Uric acid reduces exercise-induced oxidative stress in healthy adults.
Uric acid (UA) possesses free-radical-scavenging properties, and systemic administration is known to increase serum antioxidant capacity. However, it is not known whether this protects against oxidative stress. The effects of raising UA concentration were studied during acute aerobic physical exercise in healthy subjects, as a model of oxidative stress characterized by increased circulating 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha) concentrations. Twenty healthy subjects were recruited to a randomized double-blind placebo-controlled crossover study, and underwent systemic administration of 0.5 g of UA in 250 ml of 0.1% lithium carbonate/4% dextrose vehicle or vehicle alone as control. Subjects performed high-intensity aerobic exercise for 20 min to induce oxidative stress. Plasma 8-iso-PGF2alpha concentrations were determined at baseline, after exercise and after recovery for 20 min. A single bout of high-intensity exercise caused a significant increase in plasma 8-iso-PGF2alpha concentrations from 35.0 +/- 4.7 pg/ml to 45.6 +/- 6.7 pg/ml (P<0.01). UA administration raised serum urate concentration from 293 +/- 16 to 487 +/- 16 micromol/l (P<0.001), accompanied by increased serum antioxidant capacity from 1786+/-39 to 1899 +/- 45 micromol/l (P<0.01). UA administration abolished the exercise-induced elevation of plasma 8-iso-PGF2alpha concentrations. High UA concentrations are associated with increased serum antioxidant capacity and reduced oxidative stress during acute physical exercise in healthy subjects. These findings indicate that the antioxidant properties of UA are of biological importance in vivo.
Waring
W S
WS
Clinical Pharmacology Unit and Research Centre, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, Scotland, UK. s.waring@ed.ac.uk
Convery
A
A
Mishra
V
V
Shenkin
A
A
Webb
D J
DJ
Maxwell
S R J
SR
D000328:Adult; D000704:Analysis of Variance; D000975:Antioxidants / Q000494:pharmacology*; D015415:Biomarkers / Q000097:blood; D018592:Cross-Over Studies; D015237:Dinoprost / Q000031:analogs & derivatives*; D004311:Double-Blind Method; D028441:F2-Isoprostanes / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects*; D005082:Physical Exertion / Q000502:physiology*; D014527:Uric Acid / Q000494:pharmacology*
D000975:Antioxidants; D015415:Biomarkers; D028441:F2-Isoprostanes; D014527:Uric Acid; C075750:8-epi-prostaglandin F2alpha; D015237:Dinoprost